Novel susceptibility loci identified in a genome-wide association study of type 2 diabetes complications in population of Latvia.

Publisher: BioMed Central Country of Publication: England NLM ID: 101319628 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-8794 (Electronic) Linking ISSN: 17558794 NLM ISO Abbreviation: BMC Med Genomics Subsets: MEDLINE

Original Publication: London : BioMed Central

Diabetes Mellitus, Type 2*; Genetic Predisposition to Disease ; Genome-Wide Association Study ; Humans ; Latvia ; Middle Aged

Background: Type 2 diabetes complications cause a serious emotional and economical burden to patients and healthcare systems globally. Management of both acute and chronic complications of diabetes, which dramatically impair the quality of patients' life, is still an unsolved issue in diabetes care, suggesting a need for early identification of individuals with high risk for developing diabetes complications.
Methods: We performed a genome-wide association study in 601 type 2 diabetes patients after stratifying them according to the presence or absence of four types of diabetes complications: diabetic neuropathy, diabetic nephropathy, macrovascular complications, and ophthalmic complications.
Results: The analysis revealed ten novel associations showing genome-wide significance, including rs1132787 (GYPA, OR = 2.71; 95% CI = 2.02-3.64) and diabetic neuropathy, rs2477088 (PDE4DIP, OR = 2.50; 95% CI = 1.87-3.34), rs4852954 (NAT8, OR = 2.27; 95% CI = 2.71-3.01), rs6032 (F5, OR = 2.12; 95% CI = 1.63-2.77), rs6935464 (RPS6KA2, OR = 2.25; 95% CI = 6.69-3.01) and macrovascular complications, rs3095447 (CCDC146, OR = 2.18; 95% CI = 1.66-2.87) and ophthalmic complications. By applying the targeted approach of previously reported susceptibility loci we managed to replicate three associations: MAPK14 (rs3761980, rs80028505) and diabetic neuropathy, APOL1 (rs136161) and diabetic nephropathy.
Conclusions: Together these results provide further evidence for the implication of genetic factors in the development of type 2 diabetes complications and highlight several potential key loci, able to modify the risk of developing these conditions. Moreover, the candidate variant approach proves a strong and consistent effect for multiple variants across different populations.

Nat Genet. 2017 Oct;49(10):1450-1457. (PMID: 28869590)
Diabet Med. 2003 Jun;20(6):442-50. (PMID: 12786677)
Diabetes. 2015 Sep;64(9):3294-304. (PMID: 25979075)
Eur J Epidemiol. 2013 Aug;28(8):621-47. (PMID: 23900608)
Ann Hum Genet. 2015 Nov;79(6):418-30. (PMID: 26411886)
Nature. 2018 Jan 25;553(7689):530. (PMID: 29258290)
Br J Dermatol. 2017 Dec;177(6):1664-1670. (PMID: 28672053)
JAMA Neurol. 2015 Jul;72(7):781-8. (PMID: 25961151)
Pharmacogenomics J. 2018 May 22;18(3):431-435. (PMID: 28696414)
Diabetes. 2007 Apr;56(4):1160-6. (PMID: 17395753)
Nat Methods. 2013 Jan;10(1):5-6. (PMID: 23269371)
J Autoimmun. 2009 May-Jun;32(3-4):158-62. (PMID: 19324521)
J Epidemiol. 2018 Aug 5;28(8):353-360. (PMID: 29576601)
BMC Med Genet. 2008 Apr 10;9:25. (PMID: 18402670)
Nat Genet. 2012 Jul 22;44(8):955-9. (PMID: 22820512)
Circulation. 2007 Jul 10;116(2):151-7. (PMID: 17576864)
J Neuropathol Exp Neurol. 2015 Aug;74(8):804-17. (PMID: 26172287)
Acta Ophthalmol. 2018 Nov;96(7):e811-e819. (PMID: 30178632)
Int J Methods Psychiatr Res. 2018 Jun;27(2):e1608. (PMID: 29484742)
Diabetes Res Clin Pract. 2019 Nov;157:107843. (PMID: 31518657)
Clin Epigenetics. 2018 Dec 27;10(1):161. (PMID: 30587240)
Nucleic Acids Res. 2020 Jan 8;48(D1):D933-D940. (PMID: 31612961)
Diabetologia. 1999 Feb;42(2):139-45. (PMID: 10064092)
J Mol Med (Berl). 2019 Jan;97(1):1-17. (PMID: 30421101)
J Huazhong Univ Sci Technolog Med Sci. 2010 Oct;30(5):575-81. (PMID: 21063837)
Diabetes. 2006 Nov;55(11):3166-74. (PMID: 17065357)
J Diabetes Metab Disord. 2014 May 08;13:55. (PMID: 24860795)
Diabetes. 2008 Aug;57(8):2176-80. (PMID: 18443200)
NPJ Genom Med. 2019 Aug 29;4:20. (PMID: 31482010)
World J Diabetes. 2013 Aug 15;4(4):114-23. (PMID: 23961321)
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5518-5524. (PMID: 27768789)
Nature. 2014 Aug 14;512(7513):190-3. (PMID: 25043022)
Nat Genet. 2010 May;42(5):376-84. (PMID: 20383146)
IUBMB Life. 2015 May;67(5):331-7. (PMID: 25988524)
Biol Open. 2013 Feb 15;2(2):238-50. (PMID: 23430395)
Nucleic Acids Res. 2020 Jan 8;48(D1):D682-D688. (PMID: 31691826)
Diabetologia. 2014 Dec;57(12):2465-74. (PMID: 25226881)
Blood. 2019 Nov 7;134(19):1645-1657. (PMID: 31420334)
Arch Neurol. 2004 Nov;61(11):1652-61. (PMID: 15534175)
Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):546-51. (PMID: 27366724)
Nucleic Acids Res. 2019 Jan 8;47(D1):D1005-D1012. (PMID: 30445434)
Nature. 2019 Jun;570(7762):514-518. (PMID: 31217584)
Aging (Albany NY). 2018 Feb 4;10(2):178-196. (PMID: 29410390)
Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):97-104. (PMID: 17318768)
PLoS Genet. 2015 Aug 25;11(8):e1005352. (PMID: 26305897)
J Diabetes Investig. 2019 Jul;10(4):951-962. (PMID: 30592156)
Rev Diabet Stud. 2012 Spring;9(1):6-22. (PMID: 22972441)
Semin Ophthalmol. 2009 Mar-Apr;24(2):87-92. (PMID: 19373692)
Obesity (Silver Spring). 2012 Dec;20(12):2431-7. (PMID: 22836685)
Physiol Rev. 2013 Jan;93(1):137-88. (PMID: 23303908)

1.1.1.2/VIAA/2/18/287 European Regional Development Fund

Keywords: Diabetic complications; Genome-wide genotyping; Type 2 diabetes mellitus

Date Created: 20210112 Date Completed: 20211125 Latest Revision: 20211125

20231215

PMC7802349

10.1186/s12920-020-00860-4

33430853